The National Amyotrophic Lateral Sclerosis Registry
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01772602 |
Recruitment Status :
Recruiting
First Posted : January 21, 2013
Last Update Posted : May 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Amyotrophic Lateral Sclerosis |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 17000 participants |
Observational Model: | Other |
Time Perspective: | Other |
Target Follow-Up Duration: | 5 Years |
Official Title: | The National Amyotrophic Lateral Sclerosis Registry |
Study Start Date : | October 2010 |
Estimated Primary Completion Date : | December 2030 |
Estimated Study Completion Date : | December 2030 |

- The National Amyotrophic Lateral Sclerosis (ALS) Registry [ Time Frame: 1 year ]To determine the incidence and prevalence of Amyotrophic Lateral Sclerosis in the US.
- Risk factors of ALS [ Time Frame: 1 year ]To learn more about the potential risk factors for ALS

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- U.S. citizens 18 years of age or older
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01772602
Contact: Paul Mehta, MD | 770-488-0556 | PMehta1@cdc.gov | |
Contact: Kevin Horton, DrPH, MSPH | 770-488-1555 | dhorton@cdc.gov |
United States, Georgia | |
CDC | Recruiting |
Atlanta, Georgia, United States, 30333 | |
Contact: Paul Mehta, MD 770-488-0556 PMehta1@cdc.gov | |
Contact: Kevin Horton, DrPH, MSPH 770-488-1555 dhorton@cdc.gov | |
Principal Investigator: Paul Mehta, MD |
Principal Investigator: | Paul Mehta, MD | Centers for Disease Control and Prevention |
Responsible Party: | Centers for Disease Control and Prevention |
ClinicalTrials.gov Identifier: | NCT01772602 |
Other Study ID Numbers: |
CDC-NCEH/ATSDR-5768 |
First Posted: | January 21, 2013 Key Record Dates |
Last Update Posted: | May 13, 2022 |
Last Verified: | May 2022 |
Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Motor Neuron Disease |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |